Austin, Texas, United States, October 27th, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent ...

Findings Presented at ECNP 2025 in Amsterdam Support the Potential for a Safe At-Home Treatment Option in Treatment-Resistant DepressionMUNICH, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon ...

MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its ...

OXFORD, England--(BUSINESS WIRE)--Beckley Psytech Ltd, a private, clinical-stage biotechnology company developing rapid-acting, short-duration psychedelic medicines for neuropsychiatric conditions, ...

Treatment with the investigational psychedelic GH001 was linked with significant improvements in TRD that persist for at ...

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually. Clinical trials demonstrated rapid and statistically ...

Compass Pathways Plc (($CMPS)) announced an update on their ongoing clinical study. Compass Pathways Plc is conducting a Phase III clinical study ...

Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point ...

Advancing Two-Pronged Approach To Bring Innovative Therapies To Market. NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent article that discussed its approach to bring preservative-free ...